

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/073131 A1

(51) International Patent Classification:

C12N 15/50 (2006.01) *C07K 14/165* (2006.01)
A61K 39/215 (2006.01) *C12N 15/11* (2006.01)
A61P 31/14 (2006.01) *C12N 15/87* (2006.01)
A61P 37/04 (2006.01)

3132188

28 September 2021 (28.09.2021) CA

(21) International Application Number:

PCT/CA2021/051419

(22) International Filing Date:

08 October 2021 (08.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

3096009	09 October 2020 (09.10.2020)	CA
3107232	26 January 2021 (26.01.2021)	CA
3113094	23 March 2021 (23.03.2021)	CA
3116284	23 April 2021 (23.04.2021)	CA
3116932	30 April 2021 (30.04.2021)	CA
3118329	12 May 2021 (12.05.2021)	CA
3128078	09 August 2021 (09.08.2021)	CA
3128660	19 August 2021 (19.08.2021)	CA

(71) Applicant: **PROVIDENCE THERAPEUTICS HOLDINGS INC.** [CA/CA]; 120, 8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA).

(72) Inventors: **MARCUSON, Eric G.**; c/o Providence Therapeutics Holdings Inc., 120, 8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA). **ABIOYE, Jumai Adeola**; c/o Providence Therapeutics Holdings Inc., 120, 8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA). **MARTIN OROZCO, Natalia**; c/o Providence Therapeutics Holdings Inc., 120, 8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA). **ARITA, Yuko**; c/o Providence Therapeutics Holdings Inc., 120, 8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA).

(74) Agent: **ROBIC S.E.N.C.R.L. / LLP**; 630, René-Lévesque W. Boulevard, 20th Floor, Montreal, Quebec, H3B 1S6 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) Title: COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19




FIG. 22

(57) Abstract: The present disclosure generally relates to compositions, formulations, methods, and/or uses of nucleic acid vaccines, specifically nucleic acid vaccines (e.g., RNA, mRNA, DNA vaccines) encoding one or more proteins, peptides, fragments or variants thereof of SARS-CoV-2 for the prevention, alleviation and/or treatment and/or prevention of COVID-19, including mitigation of physiologic effects of infection and/or symptoms.

[Continued on next page]

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE